May 2, 2006 – Vical gained 30% after reporting its flu vaccine was 100% effective against bird flu in animal studies; Cephalon announced provisional acceptance of its wakefulness drug Nuvigil; Critical Therapeutics said the FDA will use just 6 months of data for approval of its asthma drug; Telik will begin a Phase III trial of its therapy for ovarian cancer; EntreMed will move a cancer drug into a Phase I trial; Myriad Genetics also began a Phase I test of its oral thrombin inhibitor; Tanox said that its HIV drug was effective; Regeneron reported its drug for wet age-related macular degeneration passed a Phase I trial; Corcept completed enrolment for a Phase III trial of a treatment for depression; and Bristol-Myers Squibb will withdraw its controversial antibiotic Tequin. The Centient Biotech 200™ was down 37 points at 3713.53, a loss of .99%. More details...
